Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04832971 | Study of ARO-ANG3 in Adults With Mixed Dyslipidemia | PHASE2 | COMPLETED | 204 | — | — | Jun 28, 2021 | Sep 25, 2024 | Dec 3, 2025 | 24 | United States, Australia +2 |
| Arm | Type | Description |
|---|---|---|
| ARO-ANG3 50 mg | EXPERIMENTAL | Two doses of ARO-ANG3 by subcutaneous (sc) injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. |
| ARO-ANG3 100 mg | EXPERIMENTAL | Two doses of ARO-ANG3 bysc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. |
| ARO-ANG3 200 mg | EXPERIMENTAL | Two doses of ARO-ANG3 by sc injection at Day 1 and Week 12 during double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. |
| Placebo | PLACEBO_COMPARATOR | Calculated volume to match active treatment by sc injection at Day 1 and Week 12 during the double-blind treatment period. Up to 8 doses of ARO-ANG3 by sc injection during the open-label extension period. |
| Name | Type | Description |
|---|---|---|
| ARO-ANG3 | DRUG | ARO-ANG3 Injection |
| Placebo | DRUG | Sterile Normal Saline (0.9% NaCl) |
Inclusion Criteria: * Based on medical history, evidence of triglycerides (TG) ≥ 150 mg/dL but ≤ 499 mg/dL * Fasting levels at Screening of LDL-C ≥ 70 mg/dL OR non-HDL-C ≥ 100 mg/dL after at least 4 weeks of stable diet and stable optimal statin therapy * Mean fasting TG ≥ 150 mg/dL and ≤ 499 mg/dL...